Everolimus

Current treatment options for patients with NETs 2:03
Current treatment options for patients with NETs
Jonathan Strosberg • 7 Jun 2021
Ribociclib plus everolimus in advanced dedifferentiated liposarcoma 3:25
Ribociclib plus everolimus in advanced dedifferentiated liposarcoma
Margaret von Mehren • 26 May 2021
VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer 4:44
VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer
Tian Zhang • 17 Feb 2021
Highlights in kidney and bladder cancer at ASCO GU 2021 4:45
Highlights in kidney and bladder cancer at ASCO GU 2021
Petros Grivas • 14 Feb 2021
Current treatment landscape for kidney cancer 5:11
Current treatment landscape for kidney cancer
Robert Jones • 15 Feb 2021
Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer 2:21
Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer
Ghassan Abou-Alfa • 21 Jan 2021
Kidney cancer at ASCO GU: PAPMET & CLEAR 2:15
Kidney cancer at ASCO GU: PAPMET & CLEAR
Jeffrey Graham • 14 Feb 2021
CABEYOND: cabozantinib beyond PD and survival outcomes in mRCC 3:24
CABEYOND: cabozantinib beyond PD and survival outcomes in mRCC
Giuseppe Procopio • 12 Feb 2021
Impact of p-mTOR expression on molecular-guided therapy in PDAC 1:32
Impact of p-mTOR expression on molecular-guided therapy in PDAC
Hossein Taghizadeh • 23 Jun 2020
CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer 5:01
CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
Cynthia X. Ma • 9 Jun 2020
Q-TWiST of lenvatinib + everolimus in advanced RCC 1:15
Q-TWiST of lenvatinib + everolimus in advanced RCC
Chung Han-Lee • 29 May 2020
Real-world: efficacy of everolimus + exemestane HR+, HER2- BC 5:45
Real-world: efficacy of everolimus + exemestane HR+, HER2- BC
Michael Gnant • 14 May 2020
Analysis of OS based on early tumor shrinkage in the phase III METEOR study 3:09
Analysis of OS based on early tumor shrinkage in the phase III METEOR study
Ignacio Duran
Achieving better response rates in metastatic RCC 1:31
Achieving better response rates in metastatic RCC
Bradley McGregor
The agents at the forefront of kidney cancer treatment 2:16
The agents at the forefront of kidney cancer treatment
Michael Atkins • 8 Feb 2018
Changing the standard of care in previously treated metastatic renal cell carcinoma 2:31
Changing the standard of care in previously treated metastatic renal cell carcinoma
Laurence Albiges • 25 Sep 2015
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals